Managed Care

 

Part D’s underuse of generics wastes $1B per year

MANAGED CARE July 2013. © MediMedia USA
The Formulary Files

Part D’s underuse of generics wastes $1B per year

Medicare Part D and the Department of Veterans Affairs (VA) are two major government payers of health benefits that use different approaches to managing prescription drug benefits, and a study that looked at managing brand-name prescription drugs shows a vast difference in efficiency.

Walid F. Gellad, MD, MPH, and colleagues reviewed brand-name diabetes medication use by Medicare beneficiaries and by a corresponding group of veterans ages 65+, all with diabetes.

“Use of brand- name drugs for Part D beneficiaries for these medications was two to three times higher than VA patients,” says Gellad, a physician and researcher at the VA Pittsburgh Healthcare System and the University of Pittsburgh.

Part D beneficiaries were more likely to use brand-name rather than generic oral hypoglycemic agents (35% vs. 13%), statins (51% vs. 18%), angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) (43% vs. 21%), and insulin analogues (75% vs. 27%) than their VA counterparts.

“We can look at the rates of generic use in the VA and use that as a benchmark. We should be able to take care of patients with diabetes using fewer brand-name agents and still maintain high quality care. I think most clinical executives know that, but here’s a concrete example of a system in which we can take good care of these patients with many fewer brand-name drugs — there’s incredible cost savings associated with that,” says Gellad. The researchers found that if Medicare were to use the same percentage of generic antidiabetes drugs as the VA, it would save $1 billion in a year.

That billion-dollar savings is within Medicare‘s reach, too. “What’s most amazing is that we don’t have to talk about whether Medicare has to negotiate drug prices — we don’t have to talk about prices of brand-name drugs at all,” says Gellad. He concedes that obtaining the savings might be easier said than done, “but it doesn’t require changing any law; it simply requires that patients be prescribed fewer brand-name drugs.”

The results show that providers can push generic rates a lot higher and maintain high-quality care. “There’s a lot to learn from the VA in how to manage a prescription drug system, which can be applied to the private sector,” says Gellad. “We all have limited resources, and we can maintain high quality care with fewer brand-name drugs.”

Prescription spending and projected spending if use of brand-name drugs should change in 4 drug groups. Patients had diabetes, were age 65+, and were in Medicare Part D in 2008.

Prescription spending and projected spending: Medicare Part D vs. VA

Source: Gellad WF, et al. Brand-Name Prescription Drug Use Among Veterans Affairs and Medicare Part D Patients With Diabetes: A National Cohort Comparison. Ann Intern Med. 2013 Jun 11. [Epub ahead of print] Available at http://tinyurl.com/q4tlmdt . Permission to use granted by Annals of Internal Medicine.

Meetings

4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015